Latest News- Parkinsons Disease (PD) Drugs Market: Carbidopa-levodopa is expected to lead the Drug Class segment during 2025-2029

The Parkinsons Disease (PD) Drugs Market is being driven by Rising prevalence of PD

The Parkinsons Disease (PD) Drugs Market is expected to grow at a CAGR of 5.7% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 1771.8 million. In the Parkinson's Disease (PD) drugs market, recent regulatory approvals are revolutionizing the therapeutic landscape by introducing innovative solutions to address longstanding treatment challenges. On August 7, 2024, the U.S. Food and Drug Administration (FDA) approved Amneal Pharmaceuticals' CREXONT (carbidopa and levodopa) extended-release capsules, providing patients with a more consistent dosing regimen. Around a month later, on October 17, 2024, AbbVie's VYALEV (foscarbidopa and foslevodopa) 24-hour subcutaneous infusion therapy received FDA approval for advanced PD patients. VYALEV offers personalized dosing throughout the day and night, delivering continuous dopaminergic stimulation that significantly reduces motor fluctuations and increases on time compared to traditional oral therapies. These regulatory approvals mark a significant step forward in offering more patient-centric and effective PD treatment options. 

Get more information on Parkinsons Disease (PD) Drugs Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Drug Class
  • Carbidopa-levodopa
  • Anticholinergics
  • Dopamine agonists
  • MAO-B inhibitors
  • Others
• Distribution Channel
  • Retail pharmacy
  • Hospital pharmacy
  • Online pharmacy
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
  • Asia
    • China
    • India
    • Japan
    • South Korea
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Rising prevalence of PD
• Growing healthcare expenditure
• Increasing awareness and education

However, the market also witnesses some limitations, which are as follows:

• Lack of disease-modifying therapies
• Side effects and long-term complications
• Growing competition from alternative therapies

Benefits of Buying Global Parkinsons Disease (PD) Drugs Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Parkinsons Disease (PD) Drugs Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Parkinsons Disease (PD) Drugs Market focuses on treatments for a neurodegenerative disease that affects movement control, leading to difficulties in daily activities such as walking. Novel therapies and research collaborations are prioritized to combat motor symptoms like tremors and rigidity. Decarboxylase inhibitors, administered orally, are among the common PD drugs available at hospital pharmacies, retail pharmacies, and online stores. Drug development is ongoing to target the Substantia nigra, an area of the brain affected by PD, in the aging population. Advanced drug delivery systems are being explored to improve treatment efficacy.

Market Research Overview

The neurodegenerative disease, Parkinson's Disease (PD), presents a significant opportunity for the global pharmaceuticals market. This market encompasses entities involved in the research and development (R&D) or production of various PD treatments, including generic and non-generic drugs. According to Technavio, the healthcare market size is determined by the consolidated revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. The expansion of the global pharmaceuticals market will be fueled by demographic shifts, with the global population aged 60 years and above projected to increase substantially. By 2050, approximately one-quarter of the US population is expected to be over 60 years old, while Europe is anticipated to reach a similar population demographic by 2030. This aging population trend will create a growing demand for PD drugs, driving market growth.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/